News from Asia Pacific: Due to delayed marriages and the rising cost of living, Taiwan has one of the lowest fertility rates in the world, but is also one of the preferred destinations for assisted reproduction in Asia. Against this backdrop, INVO Bioscience Inc recently signed an exclusive agreement with Ming Mei Technology to distribute INVOcell intravaginal culture (IVC) system. This is expected to bring the latest and most advanced assisted fertility treatments to individuals in Taiwan.
Demand for fertility treatments set to increase
GlobalData, a leading data, and analytics company reports that the growth prospects for advanced assisted fertility treatments in Taiwan is gaining momentum. They say the latest exclusive agreement between INVO Bioscience with Ming Mei Technology which will most likely be a catalyst for more growth in treatment protocols for infertility.
INVO Bioscience Inc aims to take advantage of Ming Mei’s reproductive medicine expertise and strong customer relationships to strengthen its presence in the region.
How the treatment works
Pratibha Thammanabhatla, Medical Devices Analyst at GlobalData, told media that IVC allows an expectant mother to carry the embryo inside her body instead of leaving it in the lab, making the process more natural, intimate, and affordable compared to other assisted reproductive technology (ART) treatments.
“The demand for this treatment is expected to increase in Taiwan as INVO Bioscience Inc claims that success rates with this technique are comparable to in vitro fertilization and substantially higher than intrauterine insemination.”
Taiwan is one of the fasted growing ART device markets in Asia Pacific
GlobalData’s report, “Assisted Reproductive Technology Devices Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030,” reveals that Taiwan is one of the fastest growing ART device markets in the Asia-Pacific region, growing at a compound annual growth rate of over 9% through 2030.
Thammanabhatla concludes: “With the availability of expertise, advanced treatment options, superior laboratory facilities, patient-centered customized treatment plans, and significant support from the Taiwanese government in the form of financial subsidy for assisted fertility services, the number of couples undergoing ART therapy in Taiwan is anticipated to grow rapidly and more companies are expected to invest in this space.
“As Taiwan lifts all its COVID-19 travel restrictions, medical tourism is also expected to increase. International patients prefer ART treatment in Taiwan considering the affordability and convenience.”
- Quotes provided by Pratibha Thammanabhatla, Medical Devices Analyst at GlobalData
- Information is based on GlobalData’s report, “Assisted Reproductive Technology Devices Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030,”
Read more about the declining sperm count among men globally.